Enanta Pharmaceuticals Inc. has patented heterocyclic compounds potentially useful for the treatment of metapneumovirus (MPV), influenza and respiratory syncytial virus (RSV) infections.
North Carolina State University has synthesized vancomycin derivatives containing a 2,3-pyrrolidinedione moiety and reported to be useful for the treatment of bacterial infections.
Uniquest Pty Ltd. has synthesized tyrosine-protein kinase SYK inhibitors reported to be useful for the treatment of allergy, cancer, fungal infections, rheumatoid arthritis, osteoporosis, liver, lung and periodontal diseases, among others.
The National Institute of Allergy and Infectious Diseases (NIAID) is set to conduct a phase I trial with Tonix Pharmaceuticals Holding Corp.’s TNX-1800 (recombinant horsepox virus, live vaccine), a vaccine candidate to protect against COVID-19.
The Coalition for Epidemic Preparedness Innovations (CEPI) and the University of Oxford have launched a new project to initiate early development of prototype vaccines against the Junín virus, selected as an exemplar of the Arenavirus family which is responsible for multiple deadly hemorrhagic fevers with epidemic and pandemic potential.
Antibiotic resistance represents a global threat that leads to high morbidity and mortality. There is an urgent need for new strategies to combat persistent and resistant bacteria.
RSS
